Global Short Bowel Syndrome Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug;
Glucagon-like Peptide-2 (GLP-2) Analog - Short-acting GLP-2 Analog[Teduglutide (Gattex/Revestive)], - Long-acting GLP-2 Analog[Glepaglutide, Apraglutide (FE 203799) and Others], Glutamine, Growth Hormone, Glucagon-like Peptide-1 (GLP-1) Analog, Insulin (NTRA 9620), TGR5 Agonist and Others.By Route of Administration;
Injectable and Oral.By Distribution Channel;
Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Short Bowel Syndrome Therapeutics Market (USD Million), 2021 - 2031
In the year 2024, the Global Short Bowel Syndrome Therapeutics Market was valued at USD 1,624.02 million. The size of this market is expected to increase to USD 6,893.56 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 22.9%.
Short bowel syndrome (SBS) presents a complex challenge in the realm of gastrointestinal disorders, characterized by the insufficient functional intestine to maintain proper nutrient absorption. This condition typically arises due to extensive surgical resection, often necessitated by conditions like Crohn's disease, mesenteric ischemia, or other gastrointestinal complications. Despite being a rare condition, its impact on patients can be profound, leading to malabsorption, dehydration, malnutrition, and other severe health complications. Consequently, the therapeutic landscape for SBS has garnered increasing attention from pharmaceutical companies and researchers aiming to address the unmet medical needs of affected individuals.
The global short bowel syndrome therapeutics market is witnessing a surge in research and development efforts aimed at novel treatment modalities to improve patient outcomes. Historically, the management of SBS has relied on supportive measures such as dietary modifications, parenteral nutrition, and in some cases, surgical interventions like intestinal transplantation. However, these approaches often come with significant limitations, including complications, cost, and reduced quality of life. As a result, there is a growing demand for more targeted and effective pharmacological interventions that can enhance intestinal adaptation, promote nutrient absorption, and mitigate the debilitating symptoms associated with SBS.
In recent years, advancements in biotechnology and pharmaceutical innovation have spurred the development of promising therapeutics tailored specifically for SBS. These include novel drugs targeting various pathways involved in intestinal function and nutrient absorption, such as growth factors, hormone analogs, bile acid modulators, and intestinal permeability enhancers. Additionally, ongoing clinical trials are exploring the potential of gene therapy, stem cell transplantation, and tissue engineering approaches to address the underlying pathophysiology of SBS and restore intestinal function. With a deepening understanding of the molecular mechanisms driving SBS, researchers are increasingly optimistic about the prospect of more targeted and personalized treatment strategies that could revolutionize the management of this challenging condition.
The global short bowel syndrome therapeutics market is poised for significant growth in the coming years, driven by a combination of technological advancements, expanding research initiatives, and increasing investment in rare disease drug development. However, key challenges remain, including the need for robust clinical evidence, regulatory hurdles, and accessibility issues. Nevertheless, with continued innovation and collaboration across the healthcare ecosystem, there is considerable optimism about the potential to improve the lives of individuals living with SBS and pave the way for more effective and sustainable treatment options in the future.
Global Short Bowel Syndrome Therapeutics Market Recent Developments
-
In September 2023, EnteraBio Ltd. entered a research collaboration agreement with OPKO Biologics, Inc., in which OPKO provided its proprietary long-acting GLP-2 peptide and Oxyntomodulin (OXM) analogs for developing oral tablet formulations targeting obesity and intestinal malabsorption syndromes using Entera's delivery technology.
-
In March 2023, Takeda Pharmaceutical Company Limited participated in the 18th European Crohn’s and Colitis Organisation (ECCO) Congress, where it shared strategies to enhance treatment adherence, discussed evolving treatment goals, and presented real-world clinical experiences related to the disease.
Segment Analysis
Short bowel syndrome (SBS) presents a challenging medical condition characterized by the inadequate absorption of nutrients due to a significantly shortened small intestine. The global market for SBS therapeutics has seen notable growth owing to the rising incidence of the syndrome, improvements in diagnosis, and advancements in treatment options. The market encompasses various approaches, including pharmacological therapies, parenteral nutrition, surgical interventions, and emerging biotechnological innovations. With the increasing recognition of the importance of tailored therapies and multidisciplinary care, the market is witnessing a shift towards personalized treatment regimens aimed at optimizing nutrient absorption and improving patients' quality of life.
Pharmacological interventions play a pivotal role in managing SBS by targeting specific symptoms and underlying mechanisms. Key players in the market continue to invest in research and development to introduce novel pharmacotherapies that address the diverse needs of patients with SBS. Additionally, advancements in parenteral nutrition formulations and delivery systems have enhanced the efficacy and safety of nutritional support, reducing the reliance on invasive procedures and minimizing associated complications. Moreover, the growing adoption of intestinal rehabilitation programs and intestinal transplantation as viable treatment options further underscores the dynamic landscape of SBS therapeutics.
The global SBS therapeutics market is also influenced by evolving regulatory frameworks and reimbursement policies, which shape market dynamics and access to innovative therapies. Collaborations between pharmaceutical companies, healthcare providers, and patient advocacy groups are fostering a holistic approach to disease management, encompassing not only medical interventions but also nutritional counseling, psychosocial support, and patient education. Furthermore, the integration of digital health technologies, such as telemedicine and remote monitoring, is poised to revolutionize care delivery and improve patient outcomes by facilitating real-time monitoring, personalized interventions, and data-driven decision-making. Overall, the global SBS therapeutics market is characterized by innovation, collaboration, and a growing emphasis on patient-centric care, driving advancements in treatment modalities and reshaping the landscape of SBS management.
Global Short Bowel Syndrome Therapeutics Segment Analysis
In this report, the Global Short Bowel Syndrome Therapeutics Market has been segmented by Drug, Route of Administration, Distribution Channel and Geography.
Global Short Bowel Syndrome Therapeutics Market, Segmentation by Drug
The Global Short Bowel Syndrome Therapeutics Market has been segmented by Drug into Glucagon-like Peptide-2 (GLP-2) Analog, Glutamine, Growth Hormone, Glucagon-like Peptide-1 (GLP-1) Analog, Insulin (NTRA 9620), TGR5 Agonist and Others.
The segment of Glucagon-like Peptide-2 (GLP-2) Analog holds a prominent position in the Short Bowel Syndrome therapeutics market. GLP-2 analogs stimulate intestinal growth and enhance nutrient absorption, thereby addressing the underlying pathology of SBS. The increasing adoption of GLP-2 analogs by healthcare professionals for managing SBS patients is expected to drive market growth in this segment.
Another vital segment in the Short Bowel Syndrome therapeutics market is Glutamine supplementation. Glutamine plays a crucial role in maintaining the integrity of the intestinal mucosa and promoting bowel adaptation in SBS patients. The rising prevalence of SBS cases worldwide has led to a greater demand for glutamine-based therapies, thereby fueling market growth in this segment.
Growth Hormone therapy represents another significant segment in the Short Bowel Syndrome therapeutics market. Growth hormone has been shown to stimulate intestinal adaptation and improve nutrient absorption in SBS patients, making it a valuable treatment option. As the understanding of SBS pathophysiology improves and new growth hormone formulations become available, this segment is anticipated to witness substantial growth in the coming years.
The market segment comprising Glucagon-like Peptide-1 (GLP-1) Analog, Insulin (NTRA 9620), TGR5 Agonist, and other emerging therapies also contribute to the overall growth of the Short Bowel Syndrome therapeutics market. With ongoing research and development efforts aimed at discovering novel therapeutic targets and treatment modalities, this segment is poised for significant expansion, providing new options for SBS patients and driving market growth further.
Global Short Bowel Syndrome Therapeutics Market, Segmentation by Route of Administration
The Global Short Bowel Syndrome Therapeutics Market has been segmented by Route of Administration into Injectable and Oral.
The market segmentation by Route of Administration highlights two primary modes: Injectable and Oral. Injectable therapies, typically administered via subcutaneous or intravenous routes, offer rapid absorption and precise dosing, making them ideal for acute management or patients with compromised oral intake. These therapies often include parenteral nutrition solutions or injectable medications aimed at addressing specific deficiencies or complications associated with SBS.
Oral therapies hold a significant share in the SBS therapeutics market, primarily due to their convenience, ease of administration, and patient compliance. Oral medications range from nutrient supplements to pharmacological agents designed to enhance intestinal adaptation, reduce symptoms, or manage complications such as bacterial overgrowth. Oral formulations are preferred for long-term maintenance therapy and are often tailored to individual patient needs, considering factors like residual bowel length and nutrient absorption capacity.
The choice between Injectable and Oral routes depends on various factors, including the severity of SBS, patient preferences, and clinical considerations such as the presence of complications like intestinal failure-associated liver disease (IFALD) or recurrent sepsis. While Injectable therapies offer immediate relief and precise control over nutrient delivery, Oral medications offer sustained benefits with fewer logistical challenges and lower risk of complications such as line infections or vascular complications associated with long-term parenteral nutrition.
Global Short Bowel Syndrome Therapeutics Market, Segmentation by Distribution Channel
The Global Short Bowel Syndrome Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
Hospital Pharmacies represent a key distribution channel for SBS therapeutics due to their ability to cater to patients receiving treatment within healthcare facilities. Hospitals often stock a wide range of medications, including specialized drugs for rare conditions like SBS. This channel provides a convenient option for patients undergoing treatment or follow-up care, ensuring timely access to prescribed medications under the supervision of healthcare professionals.
Retail Pharmacies also serve as an important distribution channel for SBS therapeutics, offering accessibility to patients outside the hospital setting. These pharmacies are often conveniently located in local communities, making it easier for patients to refill prescriptions or access over-the-counter medications as part of their SBS management plan. Retail pharmacies play a crucial role in ensuring continuity of care for SBS patients, providing a familiar and accessible avenue for medication procurement.
With the increasing prevalence of e-commerce, Online Pharmacies have emerged as a rapidly growing distribution channel for SBS therapeutics. These digital platforms offer the convenience of ordering medications from the comfort of one's home and have expanded access to SBS therapeutics for patients in remote areas or those with mobility constraints. Online pharmacies often provide a wide selection of medications, including specialized formulations for SBS, coupled with doorstep delivery services, enhancing convenience and accessibility for patients.
Global Short Bowel Syndrome Therapeutics Market, Segmentation by Geography
In this report, the Global Short Bowel Syndrome Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Short Bowel Syndrome Therapeutics Market Share (%), by Geographical Region, 2024
In North America, particularly the United States and Canada, the market is poised for significant expansion due to factors such as a well-established healthcare infrastructure, high prevalence of short bowel syndrome cases, and robust research and development activities in the pharmaceutical sector. Moreover, favorable reimbursement policies and increased awareness about the condition among healthcare professionals and patients further drive market growth in this region.
In Europe, countries like Germany, the United Kingdom, and France are witnessing substantial growth in the short bowel syndrome therapeutics market. This growth can be attributed to the rising incidence of gastrointestinal disorders, increasing healthcare expenditure, and the presence of key market players investing in the development of innovative therapies for short bowel syndrome. Additionally, government initiatives aimed at improving healthcare access and quality contribute to market expansion in this region.
The Asia Pacific region presents lucrative opportunities for market players operating in the short bowel syndrome therapeutics market. Countries such as China, Japan, and India are experiencing a surge in the prevalence of gastrointestinal disorders, including short bowel syndrome, primarily due to changing dietary patterns, lifestyle factors, and an aging population. Furthermore, growing healthcare infrastructure, increasing disposable income, and rising investments in healthcare R&D are driving market growth in this region.
In the Middle East and Africa (MEA) region, the short bowel syndrome therapeutics market is gradually evolving, supported by factors such as improving healthcare infrastructure, rising awareness about gastrointestinal disorders, and government initiatives to enhance healthcare access. However, market growth in this region may face challenges such as limited healthcare resources and infrastructure in certain areas.
Latin America represents another emerging market for short bowel syndrome therapeutics. Countries like Brazil, Mexico, and Argentina are witnessing a growing burden of gastrointestinal diseases, creating opportunities for market expansion. Moreover, collaborations between pharmaceutical companies and healthcare organizations, along with increasing investments in healthcare infrastructure, are expected to drive market growth in this region.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Short Bowel Syndrome Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers
- Technological advancements
- Increasing healthcare expenditure
- Rising prevalence of short bowel syndrome
-
Growing demand for effective treatments: The Global Short Bowel Syndrome (SBS) Therapeutics Market is experiencing substantial growth driven by the increasing demand for effective treatments. Short Bowel Syndrome, a condition characterized by malabsorption due to significant loss of functional small intestine, requires specialized therapeutic interventions to manage the complex nutritional deficiencies and associated complications. The rising prevalence of SBS, driven by factors such as increased survival rates of preterm infants and advancements in surgical procedures, has heightened the need for innovative and effective treatment options. This has spurred significant investments in research and development, leading to the introduction of novel therapies that improve patient outcomes and quality of life.
One of the critical drivers of this market is the development and approval of advanced pharmacological therapies. Recent years have seen the introduction of GLP-2 analogs like teduglutide, which enhances intestinal absorption and reduces the dependence on parenteral nutrition. These advancements represent a significant shift from traditional management strategies, which primarily focused on dietary modifications and parenteral nutrition. The increasing adoption of such innovative treatments is bolstered by clinical evidence demonstrating their efficacy in promoting intestinal adaptation and improving nutritional absorption, thereby offering a more sustainable and less invasive option for patients with SBS.
The market growth is supported by favorable regulatory environments and increased awareness among healthcare professionals and patients. Regulatory agencies like the FDA and EMA have granted orphan drug status to several SBS therapies, facilitating faster approval processes and encouraging pharmaceutical companies to invest in this niche market. Public and private healthcare providers are also playing a crucial role by incorporating SBS treatments into reimbursement programs, making these therapies more accessible to a broader patient population. As awareness of SBS and its management continues to grow, the demand for effective therapeutics is expected to rise, driving further innovation and expansion in the global SBS therapeutics market.
Restraints
- Limited awareness
- High treatment costs
- Stringent regulatory requirements
-
Side effects of existing therapies: The global short bowel syndrome (SBS) therapeutics market has been evolving rapidly due to advancements in medical treatments and increased understanding of the condition. SBS, a malabsorption disorder resulting from significant resection of the small intestine, poses significant treatment challenges. Therapeutics for SBS aim to enhance nutrient absorption, improve hydration, and minimize complications. Current treatments include parenteral nutrition (PN), enteral nutrition, and various pharmacological agents like teduglutide (Gattex) and somatropin (Zorbtive). Despite these advancements, the market is driven by the need for more effective therapies that offer better patient outcomes and fewer side effects.
Existing therapies for SBS, while beneficial, come with a range of side effects that can impact patient quality of life. Parenteral nutrition, often essential for patients with severe SBS, carries risks such as catheter-related infections, liver disease, and metabolic bone disease. Long-term dependence on PN can lead to complications like hepatic steatosis, cholestasis, and even liver failure. Pharmacological treatments like teduglutide, a glucagon-like peptide-2 analog, have been shown to reduce PN dependence but are associated with side effects including abdominal pain, nausea, and injection site reactions. Additionally, somatropin, a growth hormone, can cause edema, joint pain, and glucose intolerance, further complicating treatment regimens for SBS patients.
The ongoing challenge for the SBS therapeutics market is to develop treatments that minimize these adverse effects while maximizing therapeutic benefits. Research is focused on newer agents that can promote intestinal adaptation and function with fewer side effects. For instance, innovative therapies like recombinant human growth hormone and glucagon-like peptide-2 analogs are being optimized to reduce systemic impacts. There is also significant interest in microbiome-based therapies and regenerative medicine approaches, which hold promise for enhancing gut health and functionality. As the market continues to grow, the emphasis remains on balancing efficacy with safety, aiming to improve the overall quality of life for individuals living with SBS.
Opportunities
- Novel drug development
- Emerging markets expansion
- Collaborative research initiatives
-
Personalized medicine approaches: The global short bowel syndrome (SBS) therapeutics market is experiencing significant growth due to increasing awareness, improved diagnostic techniques, and advancements in treatment options. SBS is a complex condition that arises from the surgical removal of a significant portion of the small intestine, leading to malabsorption and various nutritional deficiencies. The market is driven by a combination of rising prevalence of gastrointestinal diseases, advancements in medical technologies, and the introduction of novel therapies. Key players in this market are investing heavily in research and development to create more effective treatments, including new pharmacological agents that can enhance intestinal absorption and mitigate the symptoms of SBS.
Personalized medicine approaches are becoming increasingly prominent in the management of short bowel syndrome. Personalized medicine involves tailoring treatment strategies to the individual characteristics of each patient, including their genetic makeup, disease presentation, and response to previous therapies. In the context of SBS, this approach can lead to more effective management of the condition by optimizing nutritional support, pharmacotherapy, and surgical interventions based on the patient's specific needs. For instance, some patients may benefit more from certain medications that enhance intestinal adaptation, while others might require specialized diets or parenteral nutrition tailored to their unique metabolic requirements.
The integration of personalized medicine into the SBS therapeutics market is expected to revolutionize patient care by improving outcomes and reducing healthcare costs. By focusing on individualized treatment plans, healthcare providers can minimize trial-and-error approaches, thereby enhancing the quality of life for patients with SBS. Additionally, advancements in genomic and proteomic technologies are enabling the identification of biomarkers that can predict treatment response, further refining the personalized approach. As these technologies continue to evolve, the market for SBS therapeutics is likely to see more targeted and effective treatment modalities, contributing to sustained growth and innovation in this specialized field of medicine.
Competitive Landscape Analysis
Key players in Global Short Bowel Syndrome Therapeutics Market include:
- Takeda Pharmaceutical Company Limited
- AbbVie Inc
- Novartis International AG
- Pfizer Inc
- Shire
- Fresenius Kabi AG
- Nestlé Health Science
- Emmaus Life Sciences, Inc
- Zealand Pharma A/S
- Nutrinia Ltd
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Global Short Bowel Syndrome Therapeutics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Technological advancements
- Increasing healthcare expenditure
- Rising prevalence of short bowel syndrome
- Growing demand for effective treatments
- Restraints
- Limited awareness
- High treatment costs
- Stringent regulatory requirements
- Side effects of existing therapies
- Opportunities
- Novel drug development
- Emerging markets expansion
- Collaborative research initiatives
- Personalized medicine approaches
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Short Bowel Syndrome Therapeutics Market, By Drug, 2021 - 2031 (USD Million)
- Glucagon-like Peptide-2 (GLP-2) Analog
- Short-acting GLP-2 Analog
- Teduglutide (Gattex/Revestive)
- Long-acting GLP-2 Analog
- Glepaglutide
- Apraglutide (FE 203799)
- Others
- Short-acting GLP-2 Analog
- Glutamine
- Growth Hormone
- Glucagon-like Peptide-1 (GLP-1) Analog
- Insulin (NTRA 9620)
- TGR5 Agonist
- Others
- Glucagon-like Peptide-2 (GLP-2) Analog
- Global Short Bowel Syndrome Therapeutics Market, By Route of Administration, 2021 - 2031 (USD Million)
- Injectable
- Oral
- Global Short Bowel Syndrome Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Short Bowel Syndrome Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Short Bowel Syndrome Therapeutics Market, By Drug, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Takeda Pharmaceutical Company Limited
- AbbVie Inc
- Novartis International AG
- Pfizer Inc
- Shire
- Fresenius Kabi AG
- Nestlé Health Science
- Emmaus Life Sciences, Inc
- Zealand Pharma A/S
- Nutrinia Ltd
- Company Profiles
- Analyst Views
- Future Outlook of the Market